身体活动作为临床前阿尔茨海默氏症疾病的可修改风险因素
Wai-Ying Wendy Yau1,2, Dylan R Kirn3, Jennifer S Rabin4,5,6
1Department of Neurology, Mass General Brigham, Boston, MA, USA. wyau@mgb.org.
Nature medicine
|November 3, 2025
概括
较高的体力活动,以每天的步骤来衡量,与老年人的认知衰退速度较慢有关,而老年人的粉样蛋白水平较高. 这种益处与降低的积有关,而不是较低的粉样蛋白水平.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 公共卫生 公共卫生
背景情况:
- 身体不活动是阿尔茨海默病 (AD) 的已知危险因素.
- 人类身体活动和AD病理进展之间的确切关系尚未完全理解.
- 这种知识差距阻碍了开发有效的AD预防试验.
研究的目的:
- 研究身体活动水平与阿尔茨海默病病理学的进展之间的关联.
- 探索粉样蛋白和积在体力活动和认知衰退之间的关系中介作用.
- 为了确定在临床前AD干预的潜在的身体活动目标.
主要方法:
- 利用计步器测量的步数来量化认知能力不受损的老年人身体活动.
- 评估了基线和纵向的粉样蛋白负担和tau积累.
- 分析了与身体活动和AD生物标志物相关的认知和功能衰退.
主要成果:
- 较高的体力活动与较慢的认知和功能衰退有关,在基线粉胺水平升高的个体中.
- 这种保护性关联与较慢的积有关,而不是减少粉样蛋白负担.
- 中等水平的体力活动 (每天5,001-7,500步) 显示了降低和认知衰退的平原效应.
结论:
- 应该将身体不活动作为改变临床前AD轨迹的干预措施.
- 干预试验可以从注册化粉样蛋白升高的久坐不动的个体中获益,以最大限度地检测身体活动的保护作用.
- 适度的体力活动可能为老年人提供一个可行的目标,以减轻AD的进展.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
Atherosclerosis III: Management
311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Parkinson's Disease: Treatment
963
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
963
Peripheral Artery Disease I: Introduction
301
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
301


